Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Business, Policy & Funding › Business News › Chembio Inks Commercialization Deal for Dengue, Zika, Chikungunya Tests

Chembio Inks Commercialization Deal for Dengue, Zika, Chikungunya Tests

May 24, 2018
|
staff reporter

NEW YORK (360Dx) – Chembio Diagnostics announced today that it has signed an agreement to commercialize its point-of-care tests for Dengue, Zika, and Chikungunya infection in Brazil with Bio-Manguinhos.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Feb
23
Featured Webinar

After the Surge: Driving Sample Processing Efficiency of Coronavirus Samples

Sponsored by
Thermo Fisher Scientific

As the world continues to contend with coronavirus and a surge in the infection rate, labs are required to run more samples than ever before. 

What's Popular?

In Infectious Disease

  1. Infectious Disease Test Firm Talis Biomedical Files for IPO

  2. Lab Stakeholders Welcome Biden Moves on COVID-19 Testing, Suggest Additional Steps

    Premium

  3. Rhinostics Licenses Procter & Gamble Nasal Swab for COVID-19 Testing

  4. Fluxergy Aiming to Provide Low-Cost, Multimodal Testing for SARS-CoV-2, Other Disease Targets

    Premium

  5. FIND, Unitaid Ink First Agreement to Enable COVID-19 Antigen Tests at $2.50 Apiece

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.